

Reason for report:

EARNINGS

XENCOR, INC.

1Q14 Recap – Pipeline on Track; Data in 4Q14

• **Bottom Line:** XNCR reported 1Q14 financial results today, and its pipeline programs remain on track. XmAb7195 Phase Ia data in healthy patients continue to be expected by the end of 2014, and XmAb5871 Phase IIa data in patients with moderate to severe rheumatoid arthritis (RA) are expected in 2H14. In addition, XNCR will move one of its two bispecific antibodies into the clinic in 2015. We are updating our model to reflect 1Q14 results. Maintain OP rating and \$17 price target in one year.

• **Data for both XmAb7195 and XmAb5871 expected in 2014.** A Phase Ia trial of XmAb7195 is expected to initiate in 1H14 that will include both healthy patients and a parallel cohort of patients with high IgE levels. Preliminary data are expected by the end of 2014, which will include IgE reduction data, likely initially in healthy patients. Top-line data from the Phase IIa trial of XmAb5871 in moderate to severe RA patients are expected in 2H14. Data will include DAS (disease activity score) 28 and ACR scores, levels of serum biomarker C-reactive protein (CRP), safety, and pharmacokinetics. The safety and activity profile will then inform next steps, which could include development in RA and other autoimmune diseases, including lupus (SLE). Recall, AMGN (MP) has an exclusive option to license this molecule until March 2017.

• **IND filing for one bispecific antibody expected in '15.** This bispecific antibody will be either a CD3 x CD38 agent that could be developed for multiple myeloma, or a CD3 x CD123 agent that could be developed for acute myelogenous leukemia (AML). XNCR expects to enter formal preclinical work in mid-2014.

• **XNCR reiterated guidance to have cash & equivalents of \$54M by end-2014.** XNCR expects its cash balance to be sufficient to fund operations through 2016. This guidance does not include additional revenue that could come from new partnerships.


• **1Q14 EPS was (\$0.12) vs. our estimate of (\$0.18).** Revenue was \$2.2M vs. our \$1.3M estimate. SG&A expense was \$1.7M vs. our \$1.3M estimate. R&D expense was \$4.2M vs. our \$5.5M estimate. Net income was (\$3.75M) vs. our (\$5.6M) estimate.

Key Stats:

(NASDAQ:XNCR)

S&P 600 Health Care Index:	1,213.11
Price:	\$8.20
Price Target:	\$17.00
Methodology:	Sum-of-the-parts discounted sales multiple
52 Week High:	\$14.41
52 Week Low:	\$5.75
Shares Outstanding (mil):	31.4
Market Capitalization (mil):	\$257.5
Cash Per Share:	\$2.31
Dividend (ann):	\$0.00
Dividend Yield:	0.0%

Shares Outstanding (mil): Total accounts for IPO, which closed 12.06.13.



Dec Yr	1Q	2Q	3Q	4Q	FY Rev	1Q	2Q	3Q	4Q	FY EPS	PE
2013A	--	--	\$8.4	\$1.7	\$10.2	--	--	(\$4.10)	(\$0.12)	(\$3.85)	NM
2014E - New	\$2.2A	\$1.3	\$1.3	\$1.3	\$5.9	(\$0.12)A	(\$0.22)	(\$0.24)	(\$0.25)	(\$0.83)	NM
2014E - Old	\$1.3	\$1.3	\$1.3	\$1.3	\$5.0	(\$0.18)	(\$0.20)	(\$0.23)	(\$0.24)	(\$0.85)	NM
2015E - New	--	--	--	--	\$10.0	--	--	--	--	(\$0.89)	NM
2015E - Old	--	--	--	--	\$10.0	--	--	--	--	(\$0.85)	NM

Source: Company Information and Leerink Partners LLC Research
Revenues in MM.

Diluted GAAP EPS; 3Q13 represents 1Q-3Q13, pre-IPO; quarterly EPS may not sum to annual total due to change in shares out.

INVESTMENT THESIS

We rate XNCR Outperform. XNCR has used its proprietary “XmAb” platform to develop an antibody pipeline focused on asthma, autoimmune diseases and cancer and also to generate incremental near-term revenue and long-term upside in form of technology licenses and partnerships. We believe XNCR’s key value drivers are its two proprietary lead product candidates XmAb7195 and XmAb5871, both addressing large market opportunities in allergic asthma and autoimmune diseases, respectively. Both programs have clinical catalysts approaching in 2H14 that could serve as early clinical validation for those agents, thus driving XNCR shares higher. In addition to that, we believe advances by XNCR’s partners and licensees could provide additional incremental cash flows while new licenses could further validate XNCR’s Fc-platform as a value driver.

Phase I IgE data in 2H14 could provide early validation for XmAb7195 as potential “biosuperior” of Xolair (Roche) for allergic asthma. We believe XmAb7195 addresses a validated target, and preclinical data have been promising thus far. Similar to Xolair, XmAb7195 is an anti-IgE mAb, but in contrast to Xolair it uses XNCR’s proprietary immune-inhibitor Fc domain, which makes it a more potent inhibitor of IgE. We believe XmAb7195 could potentially be more efficacious in patients eligible for Xolair and potentially efficacious in 20% of patients who are currently ineligible for Xolair therapy due to body weight/IgE level limitations. We believe XmAb7195 could potentially address a patient population that is 20% larger than that of Xolair, which generated \$1.3Bn in global sales in 2012.

XmAb5871 is a unique B-Cell inhibitor with first Phase IIa rheumatoid arthritis (RA) data in 2H14. XmAb5871 simultaneously targets the B-cell proteins CD19 and FcγRIIb -- which could have potential advantages over rituximab (anti-CD20), which has only limited utility in treating autoimmune diseases. XmAb5871 Phase Ia data show immunosuppression with only transient B-cell reduction and Phase IIa disease activity data in RA in 2H14 should provide further proof-of-concept for XmAb5871. We believe XmAb5871 could potentially be developed for a wide range of autoimmune diseases, including RA, lupus, or Sjögren syndrome, among others. Positive Phase IIa data in 2H14, in our view, also increase the likelihood of partner AMGN to license the product following a larger controlled Phase IIb trial.

MOR208 is an antibody targeting CD19 -- which contains XNCR’s high antibody-dependent cell cytotoxicity (ADCC) Fc domain -- outlicensed to MorphoSys (MOR), which is currently conducting two Phase II trials in acute lymphoblastic leukemia (ALL) and Non Hodgkin’s Lymphoma (NHL). An investigator-sponsored study in chronic lymphocytic leukemia (CLL) is ongoing, and data from all three studies potentially in 2015 could validate MOR208’s activity.

VALUATION

We estimate a \$17 per share price target in 12 months for XNCR based on a discounted sales multiple analysis. We apply a 12% discount rate to probability of success-weighted 2025E XmAb7195 (20%), XmAb5871 (20%), MOR208 (30%), CD3XCD38 (15%), and CD3XCD123 (15%) derived revenues. Our probability of success rates are higher than the industry average of 9% for Phase I stage therapeutics, given our higher conviction of the respective programs’ success rates. We apply a 6X multiple to XmAb7195 sales, reflecting current trailing Midcap (\$1-\$10Bn) biotech industry average and a 10X multiple to royalty streams for XmAb 5871, MOR208, CD3XCD38, and CD3XCD123. We also value XNCR’s XmAb platform at \$150MM. Based on our sum-of-parts analysis, we attribute ~\$4/share to XmAb7195, ~\$3/share to XmAb 5871, ~\$2/share to MOR208, ~\$2/share to the bispecific antibodies. We also attribute ~\$5/share to the XmAb platform and ~\$2/share to expected cash in 12 months.

RISKS TO VALUATION

Early stage developmental pipeline agents face high clinical and regulatory development risk, as well as commercial and competitive risks. As small-cap biotech company, XNCR also faces execution risk and financial risk. We estimate that XNCR’s current cash will be sufficient to fund operations through 2016 assuming continued development of XmAb8195 and XmAb 5871, and the company may have additional financing needs before turning cash flow positive.

XNCR P&L (in \$ MMs)	2011	2012	2013	1Q14	2Q14E	3Q14E	4Q14E	2014E	2015E	2016E	2017E	2018E
Collaboration and licensing revenue	6.8	9.5	10.2	2.2	1.3	1.3	1.3	5.9	10.0	10.0	20.0	25.0
Product sales	-	-	-	-	-	-	-	-	-	-	-	-
Royalty revenue	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue	6.8	9.5	10.2	2.2	1.3	1.3	1.3	5.9	10.0	10.0	20.0	25.0
COGS	-	-	-	-	-	-	-	-	-	-	-	-
R&D	12.7	12.7	17.0	4.2	6.2	6.9	7.2	24.5	30.0	36.0	39.6	43.6
SG&A	3.6	3.1	3.7	1.7	1.8	1.9	2.0	7.4	8.0	8.8	9.7	10.6
Operating expenses	16.3	15.8	20.7	6.0	8.0	8.8	9.2	32.0	38.0	44.8	49.3	54.2
Operating income	(9.5)	(6.2)	(10.5)	(3.8)	(6.8)	(7.6)	(8.0)	(26.0)	(28.0)	(34.8)	(29.3)	(29.2)
Total other income (expense)	(1.8)	(2.4)	(49.7)	0.0	-	-	-	0.0	-	-	-	-
EBT	(11.2)	(8.6)	(60.3)	(3.8)	(6.8)	(7.6)	(8.0)	(26.0)	(28.0)	(34.8)	(29.3)	(29.2)
Income tax expense	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)	(11.2)	(8.6)	(60.3)	(3.8)	(6.8)	(7.6)	(8.0)	(26.0)	(28.0)	(34.8)	(29.3)	(29.2)
Diluted EPS	(154.95)	(118.86)	(3.85)	(0.12)	(0.22)	(0.24)	(0.25)	(0.83)	(0.89)	(0.84)	(0.71)	(0.71)
Diluted shares outstanding	0.1	0.1	15.6	31.4	31.4	31.4	31.4	31.4	31.4	41.4	41.4	41.4

Source: Leerink Partners Estimates and Company Filings

BS & CFS	2011	2012	2013	1Q14	2Q14E	3Q14E	4Q14E	2014E	2015E	2016E	2017E	2018E
Cash and STI	14.5	2.3	78.0	72.5	66.4	59.6	52.4	54.5	30.3	100.0	75.7	51.9
Debt	18.5	20.9	-	-	-	-	-	-	-	-	-	-

Source: Leerink Partners Estimates and Company Filings

	Valuation (\$MM)	Per Share
XmAb7195 (20% p/w)	113	\$ 3.61
XmAb5871 (20% p/w)	80	\$ 2.55
MOR208 (30% p/w)	54	\$ 1.71
CD3XCD38 (15% p/w)	46	\$ 1.48
CD3XCD123 (15% p/w)	23	\$ 0.73
XmAb Platform	150	\$ 4.78
Total EV	466	\$ 14.86
Cash (2014E)	55	\$ 1.74
Price Target	520	\$ 17
Diluted shares outstanding (2014E)	31	

Source: Leerink Partners Estimates and Company Filings

Agent	Target	Platform	Indication	Status	Event	Timing
XmAb5871	CD19	Immune-inhibitory FcγRIIb domain	Autoimmune	Phase Ib/IIa	File IND	1H14
					Phase IIa RA data	2H14
					Initiate Phase IIb	1H15
					Phase IIb data	1H17
					AMGN option exercise	1H17
					Initiate Phase III, RA/SLE	2H17
XmAb7195	IgE	Immune-inhibitory FcγRIIb domain	Asthma	preclinical	Initiate Phase Ia	2Q14
					Phase Ia data	4Q14
					Initiate Phase Ib	1Q15
					Phase Ib data	1H16
					Initiate Phase II POC	1H16
					Phase II POC data	1H18
MOR208/XmAb5574	CD19	ADCC enhancing FcγRIIIa domain	Hematological Cancers	Phase II	Phase II data NHL	4Q15
					Phase II data ALL	4Q15

Source: Company Filings and Leerink Partners Estimates

Disclosures Appendix

Analyst Certification


I, Michael Schmidt, Ph.D., certify that the views expressed in this report accurately reflect my views and that no part of my compensation was, is, or will be directly related to the specific recommendation or views contained in this report.

Valuation


We estimate a \$17 per share price target in 12 months for XNCR based on a discounted sales multiple analysis. We apply a 12% discount rate to probability of success-weighted 2025E XmAb7195 (20%), XmAb5871 (20%), MOR208 (30%), CD3XCD38 (15%), and CD3XCD123 (15%) derived revenues. Our probability of success rates are higher than the industry average of 9% for Phase I stage therapeutics, given our higher conviction of the respective programs' success rates. We apply a 6X multiple to XmAb7195 sales, reflecting current trailing Midcap (\$1-\$10Bn) biotech industry average and a 10X multiple to royalty streams for XmAb 5871, MOR208, CD3XCD38, and CD3XCD123. We also value XNCR's XmAb platform at \$150MM. Based on our sum-of-parts analysis, we attribute ~\$4/share to XmAb7195, ~\$3/share to XmAb 5871, ~\$2/share to MOR208, ~\$2/share to the bispecific antibodies. We also attribute ~\$5/share to the XmAb platform and ~\$2/share to expected cash in 12 months.

Risks to Valuation

Early stage developmental pipeline agents face high clinical and regulatory development risk, as well as commercial and competitive risks. As small-cap biotech company, XNCR also faces execution risk and financial risk. We estimate that XNCR's current cash will be sufficient to fund operations through 2016 assuming continued development of XmAb8195 and XmAb 5871, and the company may have additional financing needs before turning cash flow positive.



Rating and Price Target History for: Amgen, Inc. (AMGN) as of 05-13-2014



Leerink Swann placed an Outperform rating on AMGN on December 17, 2010. On June 11, 2013, Leerink Swann began a transition to specific price targets for the stocks under its coverage, replacing valuation ranges.

OP=Outperform MP=Market Perform UP=Underperform D=Drop Coverage I=Initiate SC=Suspend Coverage

Created by BlueMatrix

Distribution of Ratings/Investment Banking Services (IB) as of 03/31/14				
Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY [OP]	131	68.23	46	35.11
HOLD [MP]	61	31.77	3	4.92
SELL [UP]	0	0.00	0	0.00

Explanation of Ratings

Outperform (Buy): We expect this stock to outperform its benchmark over the next 12 months.

Market Perform (Hold/Neutral): We expect this stock to perform in line with its benchmark over the next 12 months.

Underperform (Sell): We expect this stock to underperform its benchmark over the next 12 months. The degree of outperformance or underperformance required to warrant an Outperform or an Underperform rating should be commensurate with the risk profile of the company.

For the purposes of these definitions the relevant benchmark will be the S&P 600® Health Care Index for issuers with a market capitalization of less than \$2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over \$2 billion.

Important Disclosures

This information (including, but not limited to, prices, quotes and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice. This is provided for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any product to which this information relates. The Firm, its officers, directors, employees, proprietary accounts and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this report. The Firm's salespeople, traders and other professionals may provide oral or written market commentary or trading strategies that are contrary to opinions expressed in this report. The Firm's proprietary accounts may make investment decisions that are inconsistent with the opinions expressed in this report. The past performance of securities does not guarantee or predict future performance. Transaction strategies described herein may not be suitable for all investors. Additional information is available upon request by contacting the Editorial Department at One Federal Street, 37th Floor, Boston, MA 02110.

Like all Firm employees, analysts receive compensation that is impacted by, among other factors, overall firm profitability, which includes revenues from, among other business units, Institutional Equities, and Investment Banking. Analysts, however, are not compensated for a specific investment banking services transaction.

MEDACorp is a network of healthcare professionals, attorneys, physicians, key opinion leaders and other specialists accessed by Leerink and it provides information used by its analysts in preparing research.

In the past 12 months, the Firm has received compensation for providing investment banking services to Xencor, Inc. .

Leerink Partners LLC makes a market in Xencor, Inc. and Amgen, Inc.

Leerink Partners LLC has acted as the manager for a public offering of Xencor, Inc. in the past 12 months.

©2014 Leerink Partners LLC. All rights reserved. This document may not be reproduced or circulated without our written authority.

Leerink Partners LLC Equity Research			
Director of Equity Research	John L. Sullivan, CFA	(617) 918-4875	john.sullivan@leerink
Associate Director of Research	Alice C. Avanian, CFA	(617) 918-4544	alice.avanian@leerink
Healthcare Strategy	John L. Sullivan, CFA	(617) 918-4875	john.sullivan@leerink
	Alice C. Avanian, CFA	(617) 918-4544	alice.avanian@leerink
Biotechnology	Howard Liang, Ph.D.	(617) 918-4857	howard.liang@leerink
	Joseph P. Schwartz	(617) 918-4575	joseph.schwartz@leerink
	Marko Kozul, M.D.	(415) 905-7221	marko.kozul@leerink
	Michael Schmidt, Ph.D.	(617) 918-4588	michael.schmidt@leerink
	Gena Wang, Ph.D., CFA	(212) 277-6073	gena.wang@leerink
	Jonathan Chang, Ph.D.	(617) 918-4015	jonathan.chang@leerink
	Paul Matteis	(617) 918-4585	paul.matteis@leerink
	Richard Goss	(617) 918-4059	richard.goss@leerink
Life Science Tools and Diagnostics	Dan Leonard	(212) 277-6116	dan.leonard@leerink
	Justin Bowers, CFA	(212) 277-6066	justin.bowers@leerink
Pharmaceuticals/Major	Seamus Fernandez	(617) 918-4011	seamus.fernandez@leerink
	Ario Arabi	(617) 918-4568	ario.arabi@leerink
	Aneesh Kapur	(617) 918-4576	aneesh.kapur@leerink
Specialty Pharmaceuticals, Generics	Jason M. Gerberry, JD	(617) 918-4549	jason.gerberry@leerink
	Christopher W. Kuehnle, JD	(617) 918-4851	chris.kuehnle@leerink
Medical Devices, Cardiology & Orthopedics	Danielle Antalffy	(212) 277-6044	danielle.antalffy@leerink
	Richard Newitter	(212) 277-6088	richard.newitter@leerink
	Ravi Misra	(212) 277-6049	ravi.misra@leerink
Healthcare Services	Ana Gupte, Ph.D.	(212) 277-6040	ana.gupte@leerink
Healthcare Technology & Distribution	David Larsen, CFA	(617) 918-4502	david.larsen@leerink
	Christopher Abbott	(617) 918-4010	chris.abbott@leerink
Sr. Editor/Supervisory Analyst	Mary Ellen Eagan, CFA	(617) 918-4837	maryellen.eagan@leerink
Supervisory Analysts	Robert Egan		bob.egan@leerink
	Amy N. Sonne		amy.sonne@leerink
Editorial	Cristina Diaz-Dickson	(617) 918-4548	cristina.diaz-dickson@leerink

New York
299 Park Avenue, 21st floor
New York, NY 10171
(888) 778-1653

Boston
One Federal Street, 37th Floor
Boston, MA 02110
(800) 808-7525

San Francisco
201 Spear Street, 16th Floor
San Francisco, CA 94105
(800) 778-1164